A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours

Abstract

Background:

Two strategies to interrogate the insulin growth factor 1 receptor (IGF-1R) pathway were investigated: vertical inhibition with dalotuzumab and MK-2206 or ridaforolimus to potentiate PI3K pathway targeting and horizontal cross-talk inhibition with dalotuzumab and MK-0752 to exert effects against cellular proliferation, angiogenesis, and stem cell propagation.

Methods:

A phase I, multi-cohort dose escalation study was conducted in patients with advanced solid tumours. Patients received dalotuzumab (10 mg kg^–1) and escalating doses of MK-2206 (90–200 mg) or escalating doses of dalotuzumab (7.5–10 mg kg^–1) and MK-0752 (1800 mg) weekly. Upon maximum tolerated dose determination, patients with low-RAS signature, high-IGF1 expression ovarian cancer were randomised to dalotuzumab/MK-2206 versus dalotuzumab/ridaforolimus, whereas patients with high IGF1/low IGF2 expression colorectal cancer received dalotuzumab/MK-0752.

Results:

A total of 47 patients were enrolled: 29 in part A (18 in the dalotuzumab/MK-2206 arm and 11 in the dalotuzumab/MK-0752 arm) and 18 in part B (6 in each arm). Dose-limiting toxicities (DLTs) for dalotuzumab/MK-2206 included grade 4 neutropenia and grade 3 serum sickness-like reaction, maculopapular rash, and gastrointestinal inflammation. For dalotuzumab/MK-0752, DLTs included grade 3 dehydration, rash, and diarrhoea. Seven patients remained on study for >4 cycles.

Conclusions:

Dalotuzumab/MK-2206 and dalotuzumab/MK-0752 combinations were tolerable. Further developments of prospectively validated predictive biomarkers to aid in patient selection for anti-IGF-1R therapies are needed.

The insulin-like growth factor pathway is commonly deregulated in cancer to maintain the malignant phenotype (Pollak, 2008; Gao et al, 2012). Two ligands, insulin growth factor 1 (IGF1) and IGF2, bind the IGF1 receptor (IGF-1R) to induce its auto-phosphorylation. The activated receptor transduces signals downstream through the MAPK and PI3K pathways (Baserga et al, 2003; Pollak, 2008; Gao et al, 2012; Pollak, 2012). High circulating IGF1 levels have been associated with increased risks of prostate (Chan et al, 1998; Rowlands et al, 2009) and colorectal (Ma et al, 1999) cancers, whereas high IGF2 levels have been associated with poor prognosis in patients with osteosarcoma (Avnet et al, 2009). Dalotuzumab (MK-0646) is a humanised IgG1 monoclonal antibody that binds IGF-1R with high affinity (Kd ∼1 nM) and selectively blocks IGF-1R (Pandini et al, 2007; Broussas et al, 2009; Atzori et al, 2011). In a phase I clinical trial of single-agent dalotuzumab, the most common adverse events were fatigue, hyperglycaemia, and back pain. Maximum tolerated dose (MTD) was not reached, and the recommended phase II dose (RP2D) was declared at 10 mg kg^–1 per week (Atzori et al, 2011).

Anti-IGF-1R monoclonal antibodies have thus far shown limited success in clinical development (Jassem et al, 2010; Guha, 2013). This lack of significant antitumour activity has partly been attributed to the resistance (Pollak, 2012; Yee, 2012; Guha, 2013). The activation of the PI3K/AKT/mTOR pathway through IGF-1R-independent mechanisms has been described as a basis of resistance to anti-IGF-1R therapy (Hägerstrand et al, 2010; Guha, 2013). AKT and mTOR inhibitors can in turn upregulate IGF-1R via feedback loops, resulting in diminished efficacy of these compounds (Di Cosimo et al, 2005; O'Reilly et al, 2006; Wan et al, 2006; Tabernero et al, 2008). An unbiased RNAi screen for enhancers of dalotuzumab efficacy revealed that blockage of the PI3K/AKT/mTOR pathway achieved the highest synergy, and thus drugs targeting this pathway were the strongest candidates for combination therapy (Di Cosimo et al, 2010).

MK-2206 is an oral, potent allosteric inhibitor of AKT1, AKT2, and AKT3 (IC₅₀ values of 5, 12, and 65 nM, respectively) (Yap et al, 2011). Its prolonged half-life (40–100 h) favoured the evaluation of several schedules in a phase I clinical trial (Biondo et al, 2011; Yap et al, 2011). The RP2Ds were 60 mg on alternating days (Yap et al, 2011) and 135–200 mg weekly (Biondo et al, 2011), with main toxicities of rash, nausea, vomiting, diarrhoea, and hyperglycaemia (Biondo et al, 2011; Yap et al, 2011).

Ridaforolimus is a non-pro-drug rapalog that has been evaluated both orally (Mita et al, 2013) and intravenously (IV; Mita et al, 2008) in phase I clinical trials. The RP2Ds were 40 mg daily (5 days on/2 days off) orally and 12.5 mg daily (5 days every 2 weeks) IV. Main adverse events included mucositis, fatigue, rash, nausea, diarrhoea, myelosuppression, and dyslipidaemia. A phase I clinical trial with dalotuzumab and ridaforolimus reported a RP2D of 10 mg kg^–1 per week and 30 mg daily (5 days on/2 days off), respectively (Di Cosimo et al, 2010). Based on the tolerability established in a subsequent phase II study in breast cancer, the doses of dalotuzumab 10 mg kg^–1 per week and ridaforolimus 20 mg daily (5 days on/2 day off) were recommended for further evaluation (Ebbinghaus et al, 2011).

The Notch pathway, implicated in the maintenance of tumour-initiating cells and enhancement of angiogenesis (Ranganathan et al, 2011; Aster and Blacklow, 2012), has demonstrated cross-talk with IGF-1R signalling (Eliasz et al, 2010; Medyouf et al, 2011; Gusscott et al, 2012). MK-0752 is an oral, potent, and specific gamma secretase inhibitor that has undergone phase I evaluation to define a RP2D of 1800 mg weekly. The main toxicities were fatigue, nausea, and diarrhoea (Krop et al, 2012). The concomitant activation of Notch and IGF-1R pathways is detected in certain cancer types, such as colorectal cancer (Naumov et al, 2012). In a panel of colorectal cancer cell lines, the combination of MK-0752 and dalotuzumab achieved greater growth inhibition than the individual single agents, with maximum activity in low IGF2 expressers (Naumov et al, 2012).

Based on the above, we conducted an open-label, parallel-dose escalation study evaluating the combinations of dalotuzumab with MK-0752 or MK-2206 in solid tumours with expansion cohorts in biomarker-positive ovarian and colon cancer patients of these phase I doublets at their RP2Ds, and an additional expansion cohort of ovarian cancer with dalotuzumab and ridaforolimus.

Patients and methods

Study design

This was a multicentre open-label phase I, parallel-arm study evaluating dalotuzumab in combination with MK-2206, MK-0752, or ridaforolimus. The primary objective of the study was to define the safety and the MTD of dalotuzumab/MK-2206 and dalotuzumab/MK-0752 doublets, whereas the secondary objective was to explore the preliminary antitumour activity in selected populations of these two regimens, as well as a third regimen of dalotuzumab and ridaforolimus for which a recommended dose for evaluation in part B of this study had been already established. Part A was dose escalation in all comers and part B was dose expansion.

Patient selection

In a retrospective analysis of a randomised phase II/III clinical trial that evaluated dalotuzumab in combination with cetuximab and irinotecan in patients with KRAS wild-type colorectal cancer, high IGF1 expression was associated with longer progression-free survival and overall survival, whereas high IGF2 expression was associated with shorter progression-free survival (Watkins et al, 2012). These findings supported the evaluation of dalotuzumab in combination with MK-0752 in patients with KRAS wild-type colorectal cancer with high IGF1 but low IGF2 expression in the expansion cohort.

A low score for a RAS signature generated in silico from three publicly available RAS pathway profiles (Sweet-Cordero et al, 2005; Bild et al, 2006; Blum et al, 2007) correlated with sensitivity to MK-2206 in a panel of breast cancer cell lines (Loboda et al, 2010). Tumour biopsies from patients with ovarian cancer have been shown to be enriched for co-expression of low RAS signature and high IGF1 expression, potential biomarkers of sensitivity to MK-2206/ridaforolimus and dalotuzumab, respectively (Haines et al, 2012), as shown with dalotuzumab combined with ridaforolimus in patient-derived xenografts (Haines et al, 2012). This preclinical work supported selection of patients with ovarian cancer with low RAS signature and high IGF1 co-expression in the expansion cohort of the arms evaluating dalotuzumab combined with MK-2206 or ridaforolimus.

Patient population

Eligible patients in part A had advanced solid tumours refractory to standard treatment. In part B, patients with KRAS wild-type colorectal cancer, high IGF1 expression but low IGF2 expression received dalotuzumab and MK-0752, whereas patients with platinum-resistant ovarian cancer, low RAS signature, and high IGF1 expression levels were randomised to receive dalotuzumab and MK-2206 arm or dalotuzumab and ridaforolimus arm. Patients must have had good performance status (ECOG 0 or 1) and adequate bone marrow, renal, and hepatic functions and coagulation parameters. Diabetic patients were allowed, provided that their fasting serum glucose was <160 mg dl^–1 and HbA1c was ⩽8%. All patients must have had measurable disease per RECIST 1.1 (Eisenhauer et al, 2009), although patients with ovarian cancer in part B were eligible without RECIST measurable disease if they were evaluable by CA125 criteria as defined by the Gynecologic Cancer InterGroup (GCIG) (Rustin et al, 2011). Patients must have recovered from the toxicity from prior surgery or prior treatment-related toxicities. Patients with systemic treatment ⩽4 weeks prior, symptomatic ascites, pleural effusion, unstable brain metastasis, or any other concurrent medical condition that would expose them to a higher risk during the study were excluded. Females of childbearing potential must have had a negative pregnancy test. Patients of childbearing potential must have used adequate contraceptive methods.

Treatment

For the part A dalotuzumab/MK-2206 arm, patients enrolled in sequential cohorts assigned to escalating MK-2206 dose levels (DLs) with a fixed dose of dalotuzumab. Each cohort received a once-weekly dose of dalotuzumab 10 mg kg^–1 IV and MK-2206 orally (PO) at one of the following DLs: 90 mg (DL1), 135 mg (DL2), 150 mg (DL2.5), or 200 mg (DL3). In the dalotuzumab/MK-0752 arm, patient cohorts received dalotuzumab 10 mg kg^–1 IV and MK-0752 1800 mg PO once weekly (DL1). In both arms, DL1 (dalotuzumab 7.5 mg kg^–1+MK-2206 90 mg once weekly or dalotuzumab 7.5 mg kg^–1+MK-0752 1800 mg once weekly) could be explored if DL1 was deemed excessively toxic. Treatment cycles were 28 days long. A modified toxicity probability interval method guided the dose escalation (Ji et al, 2010; Ji and Wang, 2013). In part B, up to 12 patients were expected to receive dalotuzumab/MK-0752 at the provisional MTD, whereas up to 24 patients were planned to be randomised to either dalotuzumab/MK-2206 at the provisional MTD or to dalotuzumab 10 mg kg^–1 IV once weekly and ridaforolimus 20 mg daily at 5 days per week PO (ratio 1 : 1).

Antitumour activity

Response was assessed by RECIST 1.1. Radiological evaluation was performed every two cycles. For patients with ovarian cancer participating in part B response was assessed by RECIST 1.1 and/or CA125 criteria. Response-evaluable patients had one baseline and at least one post-baseline CT scan that were reviewed independently by the central imaging vendor.

Dose-limiting toxicities

Dose-limiting toxicities (DLTs) were assessed according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 (http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf). Patients were considered DLT evaluable if they have experienced a DLT during cycle 1 or have completed cycle 1 without a DLT. Any missed dose because of any reason other than toxicity would have made the patient DLT inevaluable.

The following treatment-related toxicities were considered as DLTs if occurring during the first cycle of treatment: grades 4 or 5 haematological toxicities (exception of neutropenia lasting <6 days), grades 3 or 4 neutropenia with fever (>38.5 °C), a persistent increase in QTc interval (>60 ms from baseline), any significant bradycardia, and any drug-related toxicity (regardless of grade) leading to a dose modification in the first cycle or causing a delay of >3 weeks from the next scheduled dose of study medication. Also, any grade 3 or worse non-haematological toxicity was a DLT, with the following exceptions: non-optimally treated grade 3 diarrhoea, vomiting, nausea, or dehydration; transient G3 transaminase elevation (<1 week); transient or non-optimally treated grades 3–4 hyperglycaemia; clinically nonsignificant, treatable, or reversible laboratory abnormalities; dalotuzumab infusion-related reactions; alopecia; inadequately treated hypersensitivity reactions. Treatment was held when patients experienced any toxicity meeting DLT criteria during any cycle of treatment. Treatment was resumed at a reduced dose if the toxicity recovered to grade ⩽1 within 3 weeks; otherwise, the patient was discontinued from the study. A patient who required >2 dose modifications for any single study drug was also discontinued.

Safety

Pretreatment patient evaluation included history and physical examination, ECOG performance status, laboratory analysis (haematology and biochemistry), electrocardiogram, audiometry, and ophthalmologic examination (only in MK-2206 arm). Physical examination and electrocardiogram were repeated at the beginning of each cycle and as clinically indicated. Audiometric assessment was repeated only if any grade ⩾2 ear disorder occurred. Ophthalmologic exam was repeated at treatment discontinuation. The other baseline assessments were repeated weekly before each treatment administration. Adverse events were graded according to the CTCAE 4.0.

Sites and recruitment

Four centres (two in the USA, one in Canada, and one in Israel) participated in part A, and nine centres (seven in the USA, one in Canada, and one in Israel) participated in part B. Three of the nine part B sites are members of Moffitt Cancer Center's Total Cancer Care (TCC) consortium. TCC also includes a secure biorepository database containing molecular data from 17 hospitals and the Moffitt Cancer Center. Potential part B patients, who had consented to TCC for the purpose of donating to the biorepository, underwent a secure pre-selection process (following established standard operating procedures) to evaluate candidacy for the clinical trial. The study was conducted in accordance with the applicable regulatory requirements. The clinical trial registration number was NCT01243762. All patients provided written informed consent. The study was approved by each centre's independent ethics committee.

Biomarker evaluation for patient selection

Archival samples from patients participating in the pre-screening study portion of the study were analysed by an external vendor (Almac Diagnostics, Craigavon, UK). After RNA extraction, samples from platinum-resistant ovarian cancer were analysed for IGF1 expression and RAS signature score. Samples from patients with colorectal cancer were analysed for IGF1 and IGF2 expression. The Rosetta/Merck Human RSTA Custom Affymetrix 1.0 microarray (Affymetrix, Santa Clara, CA, USA; GEO accession number GPL6793) was used to evaluate the RAS signature. Specific TaqMan-based assays were designed by Almac Diagnostics to determine the IGF1 and IGF2 mRNA levels by qRT-PCR.

For ovarian cancer samples, biomarker eligibility cut points were chosen conceptually, to broadly exclude potentially resistant tumours. Biomarker positivity was defined as a RAS score below the 50th percentile (⩽ −0.148) and IGF1 expression above the 75th percentile (ΔΔCt⩽1.44) of Almac validation samples. For colorectal cancer samples, biomarker eligibility cut points were based upon data from a retrospective analysis of a phase II/III Merck clinical study in metastatic colon cancer. Biomarker positivity was defined as IGF1 expression above the 75th percentile (ΔΔCt<2.03) and IGF2 expression below the top 10th percentile (ΔΔCt>−2.87). These thresholds could be adjusted during the pre-screening process to ensure that the positivity rate ranged between 15% and 50% of the analysed samples.

Pharmacokinetic analysis

Pre-dose samples were collected weekly during cycle 1 and on day 1 of subsequent cycles. Dalotuzumab concentration in serum was determined by an external lab via ELISA that captured dalotuzumab using the extracellular domain of recombinant human IGF-1R. Murine anti-human IgG FC antibodies conjugated to horseradish peroxidase were used to detect the captured dalotuzumab. The lower detection limit of dalotuzumab was 20 ng ml^–1 (Atzori et al, 2011). MK-2206 and MK-0752 plasma concentrations were determined as previously described (Yap et al, 2011; Krop et al, 2012) by high-performance liquid chromatography with tandem mass spectroscopy (HPLC-MS/MS) at Merck Research Labs (West Point, PA, USA). Validation data documented adequate specificity, precision, and accuracy of the HPLC-MS/MS assay used for the study. Ridaforolimus and rapamycin concentrations were assessed in whole blood samples by an external lab using chromatography with tandem mass spectroscopy. Analyses for compartmental modelling were performed using WINNonlin Pro, Version 4.1 (Pharsight Corp, Mountain View, CA, USA) (Mita et al, 2008).

Statistical analysis

Standard descriptive statistics, such as the mean, median, range, and proportion, have been used to summarise the patient characteristics and frequency of adverse events. Categorical variables have been expressed as frequencies and percentages. Continuous variables have been summarised by their mean and range or their mean and s.d.

Results

Patient demographics

From December 2010 to February 2013, 47 patients participated in the clinical trial. Twenty-nine patients participated in part A (18 in the dalotuzumab/MK-2206 arm and 11 in the dalotuzumab/MK-0752 arm). In part B, 258 patients with ovarian cancer participated in the biomarker pre-screening; 32 patients (12.4%) were biomarker positive; among them, 13 signed consent and 12 (4.7%) were eligible and randomised (1 : 1) to receive treatment with dalotuzumab and MK-2206 or dalotuzumab and ridaforolimus. In the dalotuzumab/MK-0752 arm, 158 patients with colorectal cancer participated in the biomarker pre-screening; 37 (23.4%) were biomarker positive, 10 signed informed consent, and 6 (3.8%) finally participated in part B. Table 1 summarises the demographic and disease characteristics of the patients who participated in the study.

Table 1. Patient characteristics.

	Dalotuzumab+MK-2206 (N=24)				Dalotuzumab+ridaforolimus (N=6)		Dalotuzumab+MK-0752 (N=17)
	Part A (n=18)		Part B (n=6)		Part B (n=6)		Part A (n=11)		Part B (n=6)
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Gender
Male	11	(61.1)	0	(0)	0	(0)	2	(18.2)	1	(16.7)
Female	7	(38.9)	6	(100)	6	(100)	9	(81.8)	5	(83.3)
Age (years)
Median	62		65		73		55		53.5
Range	36–74		56–76		51–85		43–73		45–86
ECOG performance status
0	12	(66.7)	3	(50.0)	3	(50.0)	0	(0)	2	(33.3)
1	6	(33.3)	3	(50.0)	3	(50.0)	11	(100)	4	(66.7)
Prior lines of systemic therapy
0	0	(0)	1	(16.7)	1	(16.7)	0	(0)	0	(0)
1	3	(16.7)	1	(16.7)	0	(0)	1	(9.1)	1	(16.7)
2	4	(22.2)	0	(0)	1	(16.7)	3	(27.3)	0	(0)
⩾3	11	(61.1)	4	(66.7)	4	(66.6)	7	(63.6)	5	(83.3)
Systemic therapy (platinum containing)
0	—	—	0	(0)	1	(16.7)	—	—	—	—
1	—	—	2	(33.3)	1	(16.7)	—	—	—	—
2	—	—	3	(50.0)	1	(16.7)	—	—	—	—
⩾3	—	—	1	(16.7)	3	(50.0)	—	—	—	—
Primary tumour type
Colorectal cancer	7	(38.9)	—	—	—	—	3	(27.2)	6	(100)
Malignant melanoma	2	(11.1)	—	—	—	—	—	—	—	—
Urothelial carcinoma	2	(11.1)	—	—	—	—	—	—	—	—
Leiomyosarcoma	2	(11.1)	—	—	—	—	1	(9.09)	—	—
NSCLC	—	—	—	—	—	—	2	(18.18)	—	—
Other tumour types:	4	(22.2)	—	—	—	—	6	(54.6)	—	—
One patient with each tumour type: endometrial stromal sarcoma, renal cell carcinoma, breast carcinoma, pancreatic carcinoma			—	—	—	—	One patient with each tumour type: malignant mesothelioma, adrenocortical carcinoma, renal cell carcinoma, oesophageal, uterine cancer		—	—
Ovarian/fallopian tube/peritoneal carcinoma	1	(5.6)	6	(100)	6	100	—	—	—	—
Gynaecological tumours: primary ovarian, fallopian tube, or primary peritoneal cancer
Ovarian cancer	0	—	4	(66.7)	5	(83.3)	—	—	—	—
Primary peritoneal	0	—	1	(16.7)	1	(16.7)	—	—	—	—
Fallopian tube	1	—	0		0		—	—	—	—
Ovary and fallopian tube		—	1	(16.7)	5	(83.3)	—	—	—	—

Abbreviations: ECOG=Eastern Cooperative Oncology Group; NSCLC=non-small cell lung cancer.

Dose escalation (part A)

Dalotuzumab+MK-2206 arm

No DLTs were observed in the three DLT-evaluable patients at DL1 (Table 2). Dose-limiting toxicities were observed in one out of six DLT-evaluable patients at DL2 (grade 3 serum sickness-like reaction) and in two of the three DLT-evaluable patients at DL3 (grade 3 maculopapular rash and grade 4 neutropenia/leukopenia). As DL3 was deemed too toxic, an intermediate DL (DL2.5) was evaluated. As none of the six DLT-evaluable patients at DL2.5 experienced a DLT, DL2.5 was considered the provisional MTD.

Table 2. DLTs, drug-related grade⩾3 toxicities beyond cycle 1, and other reasons for dose reduction.

Dose level	Drug combination	n	DLT-evaluable patients	DLTs	Toxicities meeting DLT criteria beyond cycle 1	Other toxicities causing dose reductions, interruption or treatment discontinuation
Dalotuzumab+MK-2206 arm
1	Dalotuzumab 10 mg kg–1+MK-2206 90 mg	3	3	—
2	Dalotuzumab 10 mg kg–1+MK-2206 135 mg	6	6	G3 serum sickness-like reaction	G3 hyperglycaemia
3	Dalotuzumab 10 mg kg–1+MK-2206 200 mg	3	3	G4 neutropenia/leukopenia G3 maculopapular rash
2.5	Dalotuzumab 10 mg kg–1+MK-2206 150 mg	6	6	—
2.5 Exp	Dalotuzumab 10 mg kg–1+MK-2206 150 mg	4	4	G3 maculopapular rash (2 patients) G3 gastrointestinal inflammation	G3 hyperglycaemia
2 Exp	Dalotuzumab 10 mg kg–1+MK-2206 135 mg	2	2	—
Dalotuzumab+ridaforolimus
	Dalotuzumab 10 mg kg–1 IV weekly + ridaforolimus 20 mg daily × 5 days weekly	6a	3	—		G3 T-wave inversion G2 pneumonitis
Dalotuzumab+MK-0752
1	Dalotuzumab 10 mg kg–1 IV+MK 1800 mg PO weekly	8b	6	G3 dehydration G3 rash		G3 ALT elevation (2 patients) G3 AST elevation G3 GGT elevation
–1	Dalotuzumab 7.5 mg kg–1 IV+MK 1800 mg PO weekly	3	3
1 Exp	Dalotuzumab 10 mg kg–1 IV+MK 1800 mg PO weekly	5c	4	1 G3 diarrhoea		G3 nausea, vomiting, and fatigue
–1 Exp	Dalotuzumab 7.5 mg kg–1 IV+MK 1800 mg PO weekly	1	1	1 G3 diarrhoea

Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; DLT=dose-limiting toxicity; GGT=Gamma-glutamyl transpeptidase; IV=intravenously; PO=orally.

^aThree patients were not DLT evaluable. One died of progressive disease before completion of cycle 1; two patients did not receive all the doses during cycle 1 because of non-treatment-related adverse events (G3 small bowel perforation and colonic obstruction and G2 herpes zoster).

^bTwo patients were not DLT evaluable because of disease progression before completion of cycle 1 (one patient radiological progression and another clinical progression).

^cOne patient was not DLT evaluable because of withdrawal of consent (declining performance status) before completion of cycle 1.

Dalotuzumab+MK-0752 arm

At DL1, two of the six DLT-evaluable patients (two additional patients were not DLT-evaluable) experienced DLTs (grade 3 dehydration and grade 3 rash). Based on the modified toxicity probability interval method, three patients were evaluated at DL-1. As none of the three DLT-evaluable patients experienced a DLT at this dose, DL1 was expanded in part B for confirmation of the RP2D as pre-established in the protocol according to the modified toxicity probability method.

Expansion cohorts (part B)

Ovarian cancer cohort

Twelve of 32 (37%) biomarker-eligible patients with recurrent platinum-resistant ovarian cancer participated in part B. One patient was a screening failure. The other 19 biomarker-eligible patients did not participate in the expansion cohort because of clinical deterioration before screening (5 patients), pursuit of other treatment options (4 patients), or inability to undergo screening before study accrual had closed (10 patients). Six biomarker-eligible patients received dalotuzumab/ridaforolimus; six received dalotuzumab/MK-2206. In the dalotuzumab/ridaforolimus arm, none of the three DLT-evaluable patients experienced a DLT; three additional patients were not DLT-evaluable. However, three of the four DLT-evaluable patients in the dalotuzumab/MK-2206 arm at DL2.5 experienced DLTs (grade 3 maculopapular rash in two patients and grade 3 gastrointestinal inflammation in one patient). It seemed that DL2.5 was too toxic; therefore, two additional patients were evaluated at DL2, neither of whom experienced a DLT.

Colorectal cancer cohort

Six of 37 (17%) biomarker-eligible patients with KRAS-wild-type colorectal cancer participated in the expansion cohort of dalotuzumab/MK-0752. Five patients were screening failures. The other 26 biomarker-eligible patients did not participate because of clinical deterioration before screening (2 patients), changed personal circumstances before screening (1 patient), or inability to undergo screening before study accrual had closed (23 patients). DL1 seemed too toxic, as one of the four DLT-evaluable patients experienced a DLT (grade 3 diarrhoea); an additional patient was not DLT-evaluable. Therefore, DL1 was evaluated in an additional patient that experienced a DLT (grade 3 diarrhoea). Based on the toxicity profile of the combination, the difficulty of identifying biomarker-positive patients and the lack of preliminary antitumour activity, this study arm was terminated.

Safety and tolerability

Dalotuzumab+MK-2206 arm

The most common treatment-related adverse event of any grade included fatigue (54%), hyperglycaemia (38%), diarrhoea (29%), dermatological adverse events, including rash (38%), maculopapular rash (29%), and dry skin (29% Table 3). Hyperglycaemia (17%), maculopapular rash (13%), and fatigue (8%) were the most common grade 3-related adverse events. Twelve patients experienced serious adverse events (SAEs), but only three SAEs were related to study medication (Supplementary Table 1): grade 3 gastrointestinal inflammation and grade 2 anaemia (one patient), both of which resolved ad integrum, and persistent grade 4 neutropenia, for which the outcome could not be assessed (patient was lost to follow-up).

Table 3. Drug-related toxicities in the dalotuzumab+MK-2206 and dalotuzumab+ridaforolimus arms (toxicities occurred in >10% of the patients or any grade⩾3 toxicity).

	Dalotuzumab 10 mg kg–1+MK-2206 arm															Dalotuzumab+ridaforolimus arm
	Dose escalation									Dose expansion						Dose expansion
	MK2206 90 mg n=3 (%)		MK-2206 135 mg n=6 (%)		MK-2206 200 mg n=3 (%)		MK-2206 150 mg n=6 (%)		All dose levels escalation n=18 (%)	MK-2206 150 mg n=4 (%)		MK-2206 135 mg n=2 (%)		All dose levels expansion n=6 (%)	All dose levels n=24 (%)	Dalotuzumab 10 mg kg–1+ridaforolimus 20 mg n=6 (%)
	G3–G4	Any grade	G3–G4	Any grade	G3–G4	Any grade	G3–G4	Any grade	Any grade	G3–G4	Any grade	G3–G4	Any grade	Any grade	Any grade	G3–G4	Any grade
Blood and lymphatic system disorders
Anaemia	—	—	—	—	1 (33.33)	1 (33.33)	—	—	1 (5.56)	—	1 (25)	—	—	1 (16.67)	2 (8.34)	—	—
Leukopenia	—	—	—	—	1 (33.33)	1 (33.33)	—	—	1 (5.56)	—	—	—	—	—	1 (4.17)	—	1 (16.67)
Neutropenia	—	—	—	—	1 (33.33)	1 (33.33)	—	—	1 (5.56)	—	—	—	—	—	1 (4.17)	—	—
Thrombocytopenia	—	—	—	—	1 (33.33)	1 (33.33)	—	—	1 (5.56)	—	—	—	—	—	1 (4.17)	—	3 (50)
Eye disorders
Dry eye	—	—	—	1 (16.67)	—	—	—	—	1 (5.56)	—	—	—	—	—	1 (4.17)	—	1 (16.67)
Gastrointestinal
Abdominal pain	—	2 (66.67)	—	—	—	—	—	—	2 (11.11)	—	—	—	—	—	2 (8.34)	1 (16.67)	1 (16.67)
Dry mouth	—	1 (33.33)	—	—	—	—	—	—	1 (5.56)	—	2 (50)	—	—	2 (33.33)	3 (12.5)	—	2 (33.33)
Diarrhoea	—	—	—	2 (33.33)	—	—	—	1 (16.67)	3 (16.67)	—	3 (75)	—	1	4 (66.67)	7 (29.17)	—	1 (16.67)
Gastrointestinal inflammation	—	—	—	—	—	—	—	—	—	1 (25)	1 (25)	—	—	1 (16.67)	1 (4.17)	—	—
Nausea	—	1 (33.33)	—	2 (33.33)	—	1 (33.33)	—	1 (16.67)	4 (22.22)	—	1 (25)	—	1 (50)	2 (33.33)	7 (29.17)	—	1 (16.67)
Oral pain	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1 (16.67)
Stomatitis	—	—	—	—	—	—	—	1 (16.67)	1 (5.56)	—	2 (50)	—	—	2 (33.33)	3 (12.5)	—	3 (50)
Vomiting	—	—	—	1 (16.67)	—	—	—	—	1 (5.56)	—	1 (25)	—	—	1 (16.67)	2 (8.34)	—	1 (16.67)
General disorders
Fatigue	—	1 (33.33)	—	6 (100)	1 (33.33)	2 (66.67)	—	2 (33.33)	11 (61.11)	1 (25)	2 (50)	—	—	2 (33.33)	13 (54.17)	1 (16.67)	1 (16.67)
Mucosal inflammation	—	1 (33.33)	—	2 (33.33)	1 (33.33)	1 (33.33)	—	—	4 (22.22)	—	—	—	—	—	4 (16.67)	—	2 (33.33)
Pyrexia	—	—	—	—	—	1 (33.33)	—	1 (16.67)	2 (11.11)	—	1 (25)	—	—	1 (16.67)	3 (12.5)	—	—
Immune system disorders
Serum sickness-like reaction	—	—	1 (16.67)	1 (16.67)	—	—	—	—	1 (5.56)	—	—	—	—	—	1 (4.17)	—	—
Injury, poisoning, and procedural complications
Infusion-related reaction	—	—	—	—	—	—	—	1 (16.67)	1 (5.56)	—	—	—	—	—	1 (4.17)	—	2 (33.33)
Investigations
ECG T-Wave inversion	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1 (16.67)	—
Weight decreased	—	—	—	3 (50)	—	1 (33.33)	—	—	4 (22.22)	—	1 (25)	—	—	1 (16.67)	5 (20.83)	—	—
Metabolism and nutrition disorders
Decreased appetite	—	—	—	3 (50)	—	3 (100)	—	—	6 (33.33)	—	2 (50)	—	—	2 (33.33)	8 (33.33)	1 (16.67)	2 (33.33)
Hypercholesterolaemia	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1 (16.67)
Hyperglycaemia	—	1 (33.33)	3 (50)	3 (50)	—	1 (33.33)	—	3	8 (44.44)	1 (25)	1 (25)	—	—	1 (16.67)	9 (37.5)	1 (16.67)	4 (66.67)
Hypertriglyceridaemia	—	—	—	—	—	—	—	—	—	—	1 (25)	—	—	1 (16.67)	1 (4.17)	1 (16.67)	2 (33.33)
Hyponatraemia	—	—	—	1 (16.67)	1 (33.33)	1 (33.33)	—	—	2 (11.11)	—	—	—	—	—	2 (8.34)	—	—
Hypophosphataemia	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1 (16.67)	—
Musculoskeletal and connective tissue disorders
Muscle spasm	—	—	—	3 (50)	—	—	—	—	3 (16.67)	—	1 (25)	—	—	1 (16.67)	4 (16.67)	1 (16.67)	1 (16.67)
Pain in extremity	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1 (16.67)
Nervous system disorders
Dysgeusia	—	—	—	—	—	—	—	1 (16.67)	1 (5.56)	—	2 (50)	—	—	2 (33.33)	3 (12.5)	—	1 (16.67)
Respiratory, thoracic, and mediastinal disorders
Cough	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1 (16.67)
Pneumonitis	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1 (16.67)
Dermatological
Dry skin	—	—	—	3 (50)	—	—	—	2 (33.33)	5 (27.78)	—	2 (50)	—	—	2 (33.33)	7 (29.17)	—	1 (16.67)
Petechiae	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1 (16.67)
Rash	—	2 (66.67)	—	3 (50)	—	—	—	3 (50)	8 (44.44)	—	—	—	1 (50)	1 (16.67)	9 (37.5)	—	—
Rash maculopapular	—	—	—	1 (16.67)	1 (33.33)	2 (66.67)	—	1 (16.67)	4 (22.22)	2 (50)	3 (75)	—	—	3 (50)	7 (29.17)	—	—

Abbreviation: ECG=electrocardiogram.

Dalotuzumab+ridaforolimus arm

Among the six patients treated, the most common treatment-related adverse events were stomatitis (three patients), mucosal inflammation (two patients), and infusion-related reaction (two patients) (Table 3). There were three grade 3 treatment-related adverse events: abdominal pain, fatigue, and ECG T-wave inversion (an SAE requiring hospitalisation). Another treatment-related SAE, grade 2 pneumonitis, was also reported. Both SAEs resolved ad integrum but required treatment discontinuation (Supplementary Table 1).

Dalotuzumab+MK-0752 arm

The most common treatment-related adverse events were nausea (65%), diarrhoea (59%), anorexia (59%), fatigue (53%), and vomiting (41%). The most common grade 3 treatment-related events included diarrhoea and dehydration (18% each) (Table 4). Six patients collectively experienced 10 treatment-related SAEs (Supplementary Table 1): infusion-related reaction (one patient); grade 3 diarrhoea, hypokalaemia, and hypophosphataemia (one patient); grade 3 dehydration (two patients); grade 4 vomiting, grade 3 nausea, grade 2 upper abdominal pain (one patient) and grade 3 diarrhoea, despite study drug reduction (one patient), which resolved with sequelae in 12 days. The remaining SAEs resolved ad integrum in ⩽15 days (study drug interrupted for six SAEs and discontinued for one).

Table 4. Drug-related toxicities in the dalotuzumab+MK-0752 arm.

	Dalotuzumab+MK-0752 1800 mg weekly arm
	Dose escalation					Dose expansion
	Dalotuzumab 7.5 mg kg–1 n=3 (%)		Dalotuzumab 10 mg kg–1 n=8 (%)			Dalotuzumab 10 mg kg–1 n=5 (%)		Dalotuzumab 7.5 mg kg–1 n=1 (%)
	G3–G4	Any grade	G3–G4	Any grade	All dose levels escalation n=11(%)	G3–G4	Any grade	G3–G4	Any grade	All dose levels expansion n=6 (%)	All dose levels n=17 (%)
Blood and lymphatic system disorders
Anaemia	1 (33.33)	1 (33.33)	—	—	1 (9.09)	—	—	—	—	—	1 (5.88)
Gastrointestinal
Abdominal distention	—	2 (66.67)	—	—	2 (18.18)	—	—	—	—	—	2 (11.76)
Abdominal pain	—	3 (100)	—	—	3 (27.27)	—	1 (20.0)	—	—	1 (16.67)	4 (23.53)
Diarrhoea	—	3 (100)	—	3 (37.5)	6 (54.54)	2 (40.0)	3 (60.0)	1 (100)	1 (100)	4 (66.67)	10 (58.82)
Nausea	—	2 (66.67)	1 (12.5)	6 (75)	8 (72.72)	1 (20.0)	3 (60.0)	—	—	3 (50.0)	11 (64.70)
Vomiting	—	2 (66.67)	—	3 (37.5)	5 (45.45)	1 (20.0)	2 (40.0)	—	—	2 (33.33)	7 (41.17)
General disorders
Chills	—	2 (66.67)	—	—	2 (18.18)	—	—	—	—	—	2 (11.76)
Fatigue	—	2 (66.67)	—	3 (37.5)	5 (45.45)	1 (20.0)	3 (60.0)	1 (100)	1 (100)	4 (66.67)	9 (52.94)
Peripheral oedema	—	2 (66.67)	—	—	2 (18.18)	—	—	—	—	—	2 (11.76)
Injury, poisoning, and procedural complications
Infusion-related reaction	—	2 (66.67)	—	—	2 (18.18)	—	1 (20.0)	—	—	1 (16.67)	3 (17.65)
Investigations
AST increased	—	—	1 (12.5)	4 (50.0)	4 (36.36)	—	1 (20.0)	—	—	1 (16.67)	5 (29.41)
ALT increased	—	—	2 (25.0)	4 (50.0)	4 (36.36)	—	1 (20.0)	—	—	1 (16.67)	5 (29.41)
Blood alkaline phosphatase	—	—	—	2 (25.0)	2 (18.18)	—	—	—	—	—	2 (11.76)
GGT increased	—	—	1 (12.5)	2 (25.0)	2 (18.18)	—	—	—	—	—	2 (11.76)
Weight decreased	—	1 (33.33)	—	1 (12.5)	2 (18.18)	—	1 (20.0)	—	—	1 (16.67)	3 (17.65)
Metabolism and nutrition disorders
Decreased appetite	—	2 (66.67)	—	5 (62.5)	7 (63.63)	—	2 (40.0)	—	1 (100)	3 (50.0)	10 (58.82)
Dehydration	—	—	1 (12.5)	2 (25.0)	2 (18.18)	2 (40.0)	3 (60.0)	—	—	3 (50.0)	5 (29.41)
Hyperglycaemia	—	—	—	1 (12.5)	1 (9.09)	—	1 (20.0)	—	—	1 (16.67)	2 (11.76)
Hypokalaemia	—	—	—	—	—	1 (20.0)	2 (40.0)	1 (100)	1 (100)	3 (50.0)	3 (17.65)
Hypophosphataemia	—	—	—	—	—	1 (20.0)	1 (20.0)	1 (100)	1 (100)	2 (33.33)	2 (11.76)
Musculoskeletal and connective tissue disorders
Arthralgia	—	3 (100)	—	—	3 (27.27)	—	—	—	—	—	3 (17.65)
Pain in extremity	1 (33.33)	2 (66.67)	—	—	2 (18.18)	—	1 (20.0)	—	—	1 (16.67)	3 (17.65)
Nervous system disorders
Headache	—	—	—	1 (12.5)	1 (9.09)	—	1 (20.0)	—	—	1 (16.67)	2 (11.76)
Respiratory, thoracic, and mediastinal disorders
Dyspnea	—	1 (33.33)	—	2 (25.0)	3 (27.27)	—	—	—	—	—	3 (17.65)
Dermatological
Rash	—	—	1 (12.5)	1 (12.5)	1 (9.09)	—	—	—	—	—	1 (5.88)
Vascular
Deep vein thrombosis	1 (33.33)	1 (33.33)	—	—	1 (9.09)	—	—	—	—	—	1 (5.88)

Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; GGT=Gamma-glutamyl transpeptidase.

Response evaluation

Dalotuzumab+MK-2206 arm

During part A, no partial or complete responses were observed among the 15 evaluable patients. In five patients, tumour remained stable for at least two cycles (Supplementary Figure 1A). Among those, four patients remained on study for four or more cycles (two colorectal cancer, one renal cell cancer, and one uterine leiomyosarcoma; Figure 1A). In part B, none of the four evaluable patients achieved a partial or complete response by RECIST 1.1 or GCIG (Supplementary Figures 1A and 2). Stable disease was reported for two patients, lasting four cycles for one of them. The tumour growth rate before participating in the study is not available; hence, conclusions on the efficacy of this combination cannot be drawn.

Figure 1.

Time on treatment for the patients in the dalotuzumab+MK-2206 and dalotuzumab+ridaforolimus (A) and dalotuzumab+MK-0752 arm (B).

Dalotuzumab+ridaforolimus arm

No patient achieved a complete or partial response by RECIST 1.1 or GCIG. Two patients were response evaluable; one experienced disease progression after one cycle of treatment. In the second patient, the disease remained stable for five cycles (Figure 1A). Similarly to the dalotuzumab/MK-2206 arm, the significance in terms of efficacy of this finding is unknown based on the lack of data on tumour growth rate before study participation.

Dalotuzumab+MK-0752 arm

All of the 12 evaluable patients (8 in part A and 4 in part B) experienced disease progression in the first radiological evaluation (Figure 1B and Supplementary Figure 1B).

Pharmacokinetics

Trough concentrations (Ctrough) after the first administration of dalotuzumab (7.5 and 10 mg kg^–1) were comparable to those observed in earlier studies at these DLs and generally exceeded the target threshold level of 25 μg ml^–1 (Table 5 and Figure 2). Accumulation upon repeated dosing at these DLs was also in line with earlier observations (Figure 2). From a comparison between the tested drug combinations in the study and comparison with earlier studies, no effect of MK-0752, MK-2206, and MK-8669 on the PK of dalotuzumab is apparent, although it should be noted that trough levels are a relatively insensitive measure for such effects (Figure 2).

Table 5. Summary of dalotuzumab, MK-2206, MK-0752, and ridaforolimus concentration on cycle 1 day 8.

	Serum dalotuzumab (μg ml–1)			Plasma MK-2206 (nmol l–1)
Treatment	N	Median	Range	N	Median	Range
Dalotuzumab (10 mg kg–1 QW)+MK-2206 (90 mg QW)	3	33.8	29.3–56.6	3	12.9	10.3–20.4
Dalotuzumab (10 mg kg–1 QW)+MK-2206 (135 mg QW)	8	52.2	45.2–102	8	29.1	0.687–41.1
Dalotuzumab (10 mg kg–1 QW)+MK-2206 (200 mg QW)	3	52.3	45.4–92.3	3	37.6	20.3–50.9
Dalotuzumab (10 mg kg–1 QW)+MK-2206 (150 mg QW)	10	63.5	43.7–86.4	10	9.08	0.736–26.7

	Serum dalotuzumab (μg ml–1)			Plasma MK-0752 (μmol l–1)
	N	Median	Range	N	Median	Range
Dalotuzumab (7.5 mg kg–1 QW)+MK-0752 (1800 mg QW)	4	39.3	16.7–91.7	3	8.06	1.49–11.6
Dalotuzumab (10 mg kg–1 QW)+MK-0752 (1800 mg QW)	11	41.7	5.69–97.9	11	1.63	BLQ–4.49

	Serum dalotuzumab (μg ml–1)			Whole blood ridaforolimus (ng ml–1)
	N	Median	Range	N	Median	Range
Dalotuzumab (10 mg kg–1 QW)+ridaforolimus (20 mg QD × 5)	2	49.6	32.5–66.7	4	86.7	3.12–184

Figure 2.

Dalotuzumab (MK-0646) (A), MK-2206 (B), and MK-0752 (C) pharmacokinetic profile. Ridaforolimus pharmacokinetic profile was not evaluable as a large proportion of samples were obtained post-dose instead of pre-dose.

A dose proportional increase of MK-2206 Ctrough levels was not discernible in patients treated with MK-2206 doses of 90, 135, 150, and 200 mg QW (Table 5 and Figure 2). MK-2206 Ctrough levels were comparable with previous studies. Upon weekly dosing with 1800 mg MK-0752 plasma, MK-0752 trough levels were comparable between the patients receiving 7.5 mg kg^–1 and those receiving 10 mg kg^–1 dalotuzumab (Table 5 and Figure 2). Owing to notable differences between scheduled pre-dose and actual sampling times (up to 2.5 h post dose) for the patients treated with the MK-8669-dalotuzumab combination, several observations exceeded the range of trough levels expected based on earlier studies (Table 5).

Discussion

Existent IGF-1R antagonists have limited anti-tumour activity as single agents (Haluska et al, 2010; Olmos et al, 2010; Atzori et al, 2011; Becerra et al, 2011; Schmitz et al, 2012; Macaulay et al, 2013; Ray-Coquard et al, 2013); as such, there is a strong interest to combine them with other drugs in an attempt to achieve synergistic effects. Similar to other combination trials involving anti-IGF-1R monoclonal antibodies, the observed adverse events in this study comprised known class-effect toxicities and no new relevant toxicities were described (Calvo et al, 2010; Di Cosimo et al, 2010; Naing et al, 2011; Quek et al, 2011). Still, in part B, the provisional MTDs for both doublets were found to be excessively toxic, requiring further evaluation of lower doses. Dalotuzumab 10 mg kg^–1 and MK-2206 135 mg were determined to be the RP2D for this treatment arm, but no RP2D could be defined for the dalotuzumab/MK-0752 arm. Many factors, including the challenges inherent in combining cross-class targeted agents, likely contributed to our observations. As previously described, the determination of MTD for MK-2206 and MK-0752 as single agents has been challenging (Yap et al, 2011; Krop et al, 2012), requiring the evaluation of different treatment schedules to optimise tolerability. The addition of dalotuzumab to each of these agents further complicated MTD delineation for these doublets. These serve to highlight the value of using the modified toxicity probability interval method to better define the MTD in comparison to the classic ‘3+3' method and the relevant role of expansion cohorts in phase I trials to better characterise toxicity profiles of targeted drugs or combinations (Manji et al, 2013). The tumour types evaluated in the expansion cohorts represent another potential factor accounting for the increased toxicity observed; patients with ovarian and colorectal cancers may be more prone to experience gastrointestinal toxicities because of prior surgical treatments and the possible abdominal involvement by metastatic disease.

This is one of the first reported phase I clinical trials using an IGF-1R monoclonal antibody in combination in which molecular profiling has been used for patient selection. We have shown that the application of a gene expression signature in combination with qRT-PCR is technically and clinically feasible, with average turnaround times from sample submission to result communication of 7 and 8 days for the colorectal and ovarian cancer groups, respectively. With these efforts, the pre-screening positivity rates in both arms were 16% and 26% for ovarian and colorectal groups, respectively. Potential areas of improvement for biomarker selection approach should be reviewed. Contributing factors to the observed differences between the biomarker-eligible rates as reported from the prior studies, the TCC database, and the actual biomarker-positive rate in our study population are multifactorial and include variances in the tissue preparation (formalin-fixed paraffin-embedded vs fresh frozen; macrodissection) and assay platform (microarray vs qPCR).

Selection of the correct biomarker with validated cut points is crucial to the success of biomarker-driven trials. Many factors affect the yield of consistent, clinically applicable results. Recently presented gene expression analysis of patients with ovarian cancer treated with ganitumab (anti-IGF-1R monoclonal antibody) in a phase II study revealed that IGF1 is one of the upregulated genes in the cluster that predicts greater benefit from the treatment (Ray-Coquard et al, 2013). This further supports our selection approach; still, the IGF1/IGF2 expression biomarker used in this study was developed from the tumour samples of patients receiving dalotuzumab combined with cetuximab (Watkins et al, 2012). Thus, it is undetermined whether it has applications to other dalotuzumab-containing combinations. In the dalotuzumab plus MK-0752 arm, the IGF1 and IGF2 expression criteria do not take into account any dependency on the Notch pathway. No Notch pathway biomarker has been prospectively validated, but some recently published potential biomarkers based on protein and gene expression could be evaluated (Zhang et al, 2013). From the lessons learned, the authors charge that biomarker studies validating clinical utility are required. This is further supported by multiple groups, including the National Cancer Institute/Cancer Therapy Evaluation Program (Dancey et al, 2010) or European Organisation for Research and Treatment of Cancer (Daidone et al, 2012).

There are currently several combinations of IGF-1R and mTOR inhibitors under evaluation in patients with breast cancer–dalotuzumab/ridaforolimus (NCT01220570, NCT01234857 (Ebbinghaus et al, 2011) and cixutumumab/temsirolimus (NCT00699491)–as responses were seen in this patient population in the initial dalotuzumab and ridaforolimus studies (Di Cosimo et al, 2010). A study (NCT01708161) evaluating ganitumab and BYL719 (PI3K α-isoform-specific inhibitor) is recruiting patients with breast or ovarian cancer. For both tumour types, only patients with PIK3CA mutations or amplifications are selected (Cao et al, 2013). It remains unknown whether a signature derived from a gene expression profile, such as the one used for patient selection in this study, could better identify activation of the PI3K/AKT/mTOR pathway, in comparison to mutations or amplifications in a single point of the pathway.

Although the high attrition rates are not surprising for a phase I clinical trial population, the accrual rates limited the evaluation of efficacy in the expansion cohorts; no arm had >4 evaluable patients. Among them, no objective response by RECIST was observed, but two patients with ovarian cancer remained on study for at least 4 months. Based on the limited number of patients, ultimately no preliminary conclusion on efficacy or on the predictive value of the current selection strategy can be established.

In conclusion, this study utilises a molecular selection approach in expansion cohorts to obtain additional safety and preliminary efficacy data, in order to facilitate developmental decisions for multiple targeted combinations. The toxicity management has been challenging, especially in the MK-0752 and dalotuzumab arm, and further alterations in treatment schedule will be necessary to overcome this problem. The patient selection process represented another relevant challenge. As molecular selection is becoming more prevalent in the clinic, the development of locally accessible, multiplexed, validated molecular profiling programs is becoming instrumental to perform relevant molecular analyses while the patient is still receiving standard treatment. Although this strategy would miss secondary mutations or changes in the microenvironment occurring because of selective pressure under standard treatment, many of the key molecular alterations would still be present in these initial samples and the results will be readily available upon treatment progression. Thus, patients could be offered tailored treatment in a timely manner.

MBJ and JDC are employees of Merck. AG was an employee of Merck when the study was conducted. PH, JF, and LLS had received research funding from Merck. The remaining authors declare no conflict of interest.